Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Beleave Inc. Announces $5 Million Non-Brokered Private Placement of Units

BLEVF

Canada NewsWire

TORONTO, June 8, 2018 /CNW/ - Beleave Inc. (CSE: BE; OTCQX: BLEVF) ("Beleave" or the "Company"), a diversified biotech company with a purpose-built ACMPR licensed cannabis facility near Hamilton, Ontario and patient services clinics operating across Ontario under the Medi-Green brand, is pleased to announce its intention to complete a non-brokered private placement (the "Non-Brokered Offering") of up to 2,500,000 units of the Company at a price of $2.00 per unit for gross proceeds of approximately $5 million. The Company has already received sufficient interest from individuals to complete the $5 million financing. The Company may, at its sole discretion, increase the size of the Non-Brokered Offering.

Beleave Inc. (CNW Group/Beleave Inc.)

Each unit ("Unit") is comprised of one common share of the Company (a "Common Share") and one-half common share purchase warrant of the Company (a "Warrant"), at a price of $2.00 per Unit. Each Warrant entitles the holder thereof to purchase one Common Share of the Company at an exercise price of $2.75 for a period of 24 months from the date of issuance of the Warrant, subject to accelerated expiry in the event that the ten-day volume weighted average price of the Common Shares on the Canadian Securities Exchange (the "CSE"), or other exchange or quotation system where the Company's shares are listed and where a majority of the trading volume of the Common Shares occurs, equals or exceeds $3.00. Subject to customary closing conditions, including CSE approval, the Non-Brokered Offering is expected to have multiple tranches, with the first tranche closing on or about June 11, 2018.

"We believe deeply in the quality of our innovations," said Beleave CEO Andrew Wnek. "We are focusing our investments in areas where we will have a direct impact for the good of our patients and shareholders alike. We thank our investors for their continued support. The capital will be used for G&A purposes and be available as we continue to evaluate a multitude of industry opportunities."

This press release has been reviewed by the Beleave Director and Chief Financial Officer Bojan Krasic.

About Beleave

Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. These risks and uncertainties include, but are not limited to, the Company's ability to satisfy the conditions associated with its cultivation license, the Company's ability to obtain a sales license and the related timing considerations, the availability of further financing, consumer interest in its products, competition, regulation, operational and technological risks, and anticipated and unanticipated costs and delays. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com .

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/beleave-inc-announces-5-million-non-brokered-private-placement-of-units-300662604.html

SOURCE Beleave Inc.

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/08/c8654.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today